Skip to main content
SpringerLink
Log in

Hypophysär bedingter Hypogonadismus, Hyperprolaktinämie und Gondadotropin-produzierende Tumoren

  • Chapter
  • First Online:
Andrologie

Part of the book series: Springer Reference Medizin ((SRM))

  • 736 Accesses

Zusammenfassung

Ein hypophysär bedingter Hypogonadismus kann erblich bedingt oder erworben sein. In den meisten Fällen sind Adenome Ursache des hypophysär bedingten Hypogonadismus. Adenome können medikamentös und/oder neurochirurgisch behandelt werden Dadurch wird oft eine Funktionstüchtigkeit wenigstens einiger Hormonachsen erreicht. Generell wird bei einer Hypophyseninsuffizienz, die nicht kausal therapiert werden kann, das Hormon am Ende der Signalkette substituiert, beim Mann ist dies Testosteron. Im Weiteren muss dann eine Gabe von Schilddrüsenhormonen, Kortisol und ggf. auch Wachstumshormon geprüft werden. Bei einem Ausfall der Neurohypophyse erfolgt die Gabe von ADH. Eine Ausnahme der sonst üblichen Testosterongabe besteht bei Kinderwunsch. Hier muss durch eine Gabe von Gonadotropinen die testikuläre Funktion mit ausreichender Testosteronproduktion und Spermatogenese induziert bzw. aufrechterhalten werden.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 239.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 249.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Literatur

  • Berezin M, Karasik A (1995) Familial prolactinoma. Clin Endocrinol (Oxf) 42:483–486

    Article  CAS  PubMed  Google Scholar 

  • Bevan JS, Webster J, Burke C, Scanlon MF (1992) Dopamine agonists and pituitary tumor shrinkage. Endocr Rev 13:220–240

    Article  CAS  PubMed  Google Scholar 

  • Biagetti B, Ferrer Costa R, Alfayate Guerra R, Álvarez García E, Berlanga Escalera E, Casals G, Esteban Salán M, Granada Ibern ML, Gorrín Ramos J, López Lazareno N, Oriola J, Sánchez Martínez PM, Torregrosa Quesada ME, Urgell Rull E, García Lacalle C (2022) Macroprolactin: from laboratory to clinical practice. Endocrinol Diabetes Nutr (Engl Ed) 69:63–69

    PubMed  Google Scholar 

  • Cannavo S, Curto L, Squadrito S, Almoto B, Vieni A, Trimarchi F (1999) Cabergoline: a first-choice treatment in patients with previously untreated prolactin-secreting pituitary adenoma. J Endocrinol Invest 22:354–359

    Article  CAS  PubMed  Google Scholar 

  • Casanueva FF, Molitch ME, Schlechte JA, Abs R, Bonert V, Bronstein MD, Brue T, Cappabianca P, Colao A, Fahlbusch R, Fideleff H, Hadani M, Kelly P, Kleinberg D, Laws E, Marek J, Scanlon M, Sobrinho LG, Wass JA, Giustina A (2006) Guidelines of the pituitary society for the diagnosis and management of prolactinomas. Clin Endocrinol (Oxf) 65:265–273

    Article  PubMed  Google Scholar 

  • Castinetti F, Albarel F, Amodru V, Cuny T, Dufour H, Graillon T, Morange I, Brue T (2021) The risks of medical treatment of prolactinoma. Ann Endocrinol (Paris) 82(1):15–19

    Article  PubMed  Google Scholar 

  • Chaidarun SS, Klibanski A (2002) Gonadotropinomas. Semin Reprod Med 20:339–348

    Article  PubMed  Google Scholar 

  • Colao A, Di Sarno A, Cappabianca P, Di Somma C, Pivonello R, Lombardi G (2003) Withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinemia. N Engl J Med 349:2023–2033

    Article  CAS  PubMed  Google Scholar 

  • Colao A, Galderisi M, Di Sarno A, Pardo M, Gaccione M, D'Andrea M, Guerra E, Pivonello R, Lerro G, Lombardi G (2008) Increased prevalence of tricuspid regurgitation in patients with prolactinomas chronically treated with cabergoline. J Clin Endocrinol Metab 93:3777–3784

    Article  CAS  PubMed  Google Scholar 

  • Dai C, Liang S, Sun B, Kang J (2020) The progress of immunotherapy in refractory pituitary adenomas and pituitary carcinomas. Front Endocrinol (Lausanne) 11:608422

    Article  PubMed  Google Scholar 

  • De Rosa M, Colao A, Di Sarno A, Ferone D, Landi ML, Zarrilli S, Paesano L, Merola B, Lombardi G (1998) Cabergoline treatment rapidly improves gonadal function in hyperprolactinemic males: a comparison with bromocriptine. Eur J Endocrinol 138:286–293

    Article  PubMed  Google Scholar 

  • Deladoey J, Flück C, Büyükgebiz A, Kuhlmann BV, Eblé A, Hindmarsh PC, Wu W, Mullis PE (1999) „Hot spot“ in the PROP1 gene responsible for combined pituitary hormone deficiency. J Clin Endocrinol Metab 84:1645–1650

    CAS  PubMed  Google Scholar 

  • Dwyer AA, Raivio T, Pitteloud N (2015) Gonadotrophin replacement for induction of fertility in hypogonadal men. Best Pract Res Clin Endocrinol Metab 29:91–103

    Article  CAS  PubMed  Google Scholar 

  • Flück C, Deladoey J, Rutishauser K, Eblé A, Marti U, Wu W, Mullis PE (1998) Phenotypic variability in familial combined pituitary hormone deficiency caused by a PROP1 gene mutation resulting in the substitution of Arg → Cys at codon 120 (R120C). J Clin Endocrinol Metab 83:3727–3734

    PubMed  Google Scholar 

  • Gillam MP, Molitch ME, Lombardi G, Colao A (2006) Advances in the treatment of prolactinomas. Endocr Rev 27:485–534

    Article  CAS  PubMed  Google Scholar 

  • Haider SA, Levy S, Rock JP, Craig JR (2022) Prolactinoma: medical and surgical considerations. Otolaryngol Clin North Am 55(2):305–314

    Article  PubMed  Google Scholar 

  • Herring N, Szmigielski C, Becher H, Karavitaki N, Wass JA (2009) Valvular heart disease and the use of cabergoline for the treatment of prolactinoma. Clin Endocrinol (Oxf) 70:104–108

    Article  PubMed  Google Scholar 

  • Ilie MD, Raverot G (2020) Treatment options for gonadotroph tumors: current state and perspectives. J Clin Endocrinol Metab 105:dgaa497

    Article  PubMed  Google Scholar 

  • Inder WJ, Jang C (2022) Treatment of prolactinoma. Medicina (Kaunas) 58:1095

    Article  PubMed  Google Scholar 

  • Jaffe CA (2006) Clinically non-functioning pituitary adenoma. Pituitary 9:317–321

    Article  PubMed  Google Scholar 

  • Karavitaki N, Thanabalasingham G, Shore HC, Trifanescu R, Ansorge O, Meston N, Turner HE, Wass JA (2006) Do the limits of serum prolactin in disconnection hyperprolactinaemia need re-definition? A study of 226 patients with histologically verified non-functioning pituitary macroadenoma. Clin Endocrinol (Oxf) 65:524–529

    Article  CAS  PubMed  Google Scholar 

  • Kars M, Pereira AM, Bax JJ, Romijn JA (2008) Cabergoline and cardiac valve disease in prolactinoma patients: additional studies during long-term treatment are required. Eur J Endocrinol 159:363–367

    Article  CAS  PubMed  Google Scholar 

  • Kelberman D, Dattani MT (2008) Septo-optic dysplasia – novel insights into the aetiology. Horm Res 69:257–265

    CAS  PubMed  Google Scholar 

  • Lagerström-Fermér M, Sundvall M, Johnsen E, Warne GL, Forrest SM, Zajac JD, Rickards A, Ravine D, Landegren U, Pettersson U (1997) X-linked recessive panhypopituitarism associated with a regional duplication in Xq25-q26. Am J Hum Genet 60:910–916

    PubMed  PubMed Central  Google Scholar 

  • Lee DH, Park JE, Nam YK, Lee J, Kim S, Kim YH, Kim HS (2021) Deep learning-based thin-section MRI reconstruction improves tumour detection and delineation in pre- and post-treatment pituitary adenoma. Sci Rep 29:21302

    Article  Google Scholar 

  • Liu PY, Baker HWG, Jayadev V (2009) Induction of spermatogenesis and fertility during gonadotropin treatment of Gonadotropin-Deficient infertile men: predictors of fertility outcome. J Clin Endocrinol Metab 94:801–808

    Article  CAS  PubMed  Google Scholar 

  • Lofrano-Porto A, Casulari LA, Nascimento PP, Giacomini L, Naves LA, da Motta LD, Layman LC (2008) Effects of follicle-stimulating hormone and human chorionic gonadotropin on gonadal steroidogenesis in two siblings with a follicle-stimulating hormone beta subunit mutation. Fertil Steril 90:1169–1174

    Article  PubMed  Google Scholar 

  • Lüdecke DK für die Expertengruppe der Arbeitsgemeinschaft Hypophyse (2003) Betreuung von Patienten mit hormoninaktiven Adenomen der Hypophyse. Med Klin 98:616–627

    Google Scholar 

  • Maiter D (2019) Management of dopamine agonist-resistant prolactinoma. Neuroendocrinology 109:42–50

    Article  CAS  PubMed  Google Scholar 

  • Mancini T, Casanueva FF, Giustina A (2008) Hyperprolactinemia and prolactinomas. Endocrinol Metab Clin North Am 37:67–99

    Article  CAS  PubMed  Google Scholar 

  • Mantovani G, Borgato S, Beck-Peccoz P, Romoli R, Borretta G, Persani L (2003) Isolated follicle-stimulating hormone (FSH) deficiency in a young man with normal virilization who did not have mutations in the FSHbeta gene. Fertil Steril 79:434–436

    Article  PubMed  Google Scholar 

  • Mehta A, Dattani MT (2008) Developmental disorders of the hypothalamus and pituitary gland associated with congenital hypopituitarism. Best Pract Res Clin Endocrinol Metab 22:191–206

    Article  CAS  PubMed  Google Scholar 

  • Melmed S (2008) Update in pituitary disease. J Clin Endocrinol Metab 93:331–338

    Article  CAS  PubMed  Google Scholar 

  • Müller OA, Emons G, Fahlbusch F, Hensen J, Ranke MB, Stalla GK, Strasburger CJ (2003) Hypothalamus und Hypophyse. In: Deutsche Gesellschaft für Endokrinologie (ed) Rationelle Diagnostik und Therapie in Endokrinologie, Diabetologie und Stoffwechsel, 2. Aufl. Thieme, Stuttgart/New York, S 7–44

    Google Scholar 

  • Nachtigall LB (2017) Cabergoline for hyperprolactinemia: getting to the heart of it. Endocrine 57:3–5

    Article  CAS  PubMed  Google Scholar 

  • Oduwole OO, Peltoketo H, Poliandri A, Vengadabady L, Chrusciel M, Doroszko M, Samanta L, Owen L, Keevil B, Rahman NA, Huhtaniemi IT (2018) Constitutively active follicle-stimulating hormone receptor enables androgen-independent spermatogenesis. J Clin Invest 128:1787–1792

    Article  PubMed  PubMed Central  Google Scholar 

  • Pitteloud N, Boepple PA, DeCruz S, Valkenburgh SB, Crowley WF Jr, Hayes FJ (2001) The fertile eunuch variant of idiopathic hypogonadotropic hypogonadism: spontaneous reversal associated with a homozygous mutation in the gonadotropin-releasing hormone receptor. J Clin Endocrinol Metab 86:2470–2475

    CAS  PubMed  Google Scholar 

  • Rastrelli G, Corona G, Maggi M (2015) The role of prolactin in andrology: what is new? Rev Endocr Metab Disord 16:233–248

    Article  CAS  PubMed  Google Scholar 

  • Rohayem J, Hauffa BP, Zacharin M, Kliesch S, Zitzmann M; “German Adolescent Hypogonadotropic Hypogonadism Study Group” (2017) Testicular growth and spermatogenesis: new goals for pubertal hormone replacement in boys with hypogonadotropic hypogonadism? -a multicentre prospective study of hCG/rFSH treatment outcomes during adolescence. Clin Endocrinol (Oxf) 86:75–87

    Article  CAS  PubMed  Google Scholar 

  • Rosenbloom AL, Almonte SA, Brown MR, Fisher DA, Baumbach L, Parks JS (1999) Clinical and biochemical phenotype of familial anterior hypopituitarism from mutations of the PROP1 gene. J Clin Endocrinol Metab 84:50–57

    CAS  PubMed  Google Scholar 

  • Saeger W, Lüdecke DK, Buchfelder M, Fahlbusch R, Quabbe HJ, Petersenn S (2007) Pathohistological classification of pituitary tumors: 10 years of experience with the German Pituitary Tumor Registry. Eur J Endocrinol 156:203–216

    Article  CAS  PubMed  Google Scholar 

  • Schlechte JA (2003) Clinical practice. Prolactinoma. N Engl J Med 349:2035–2041

    Article  CAS  PubMed  Google Scholar 

  • Schlechte JA (2007) Long-term management of prolactinoma. J Clin Endocrinol Metab 92:2861–2865

    Article  CAS  PubMed  Google Scholar 

  • Shaid M, Korbonits M (2017) Genetics of pituitary adenomas. Neurol India 65:577–587

    Article  PubMed  Google Scholar 

  • Sherlock M, Toogood AA, Steeds R (2009) Dopamine agonist therapy for hyperprolactinaemia and cardiac valve fibrosis; a lot done but much more to do. Heart 95(7):522–523

    Article  CAS  PubMed  Google Scholar 

  • Solomon NM, Ross SA, Morgan T, Belsky JL, Hol FA, Karnes PS, Hopwood NJ, Myers SE, Tan AS, Warne GL, Forrest SM, Thomas PQ (2004) Array comparative genomic hybridisation analysis of boys with X linked hypopituitarism identifies a 3.9 Mb duplicated critical region at Xq27 containing SOX3. J Med Genet 41:669–678

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Werder K von (1995) Alte und neue Therapieoptionen bei der Hyperprolaktinämie. In: Allolio B, Grußendorf M, Müller OA, Olbricht T, Schulte HM (Hrsg) Syllabus des III. Intensivkursus für Klinische Endokrinologie. Bundesdruckerei, Neu-Isenburg, S 108–115

    Google Scholar 

  • Willnow S, Kiess W, Butenandt O, Dörr HG, Enders A, Strasser-Vogel B, Egger J, Schwarz HP (1996) Endocrine disorders in septo-optic dysplasia (De Morsier syndrome) – evaluation and follow up of 18 patients. Eur J Pediatr 155:179–184

    Article  CAS  PubMed  Google Scholar 

  • Yao A, Rutland JW, Verma G, Banihashemi A, Padormo F, Tsankova NM, Delman BN, Shrivastava RK, Balchandani P (2020) Pituitary adenoma consistency: Direct correlation of ultrahigh field 7T MRI with histopathological analysis. Eur J Radiol 126:108931

    Article  PubMed  Google Scholar 

  • Zanettini R, Antonini A, Gatto G, Gentile R, Tesei S, Pezzoli G (2007) Valvular heart disease and the use of dopamine agonists for Parkinson's disease. N Engl J Med 356:39–46

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Centrum für Reproduktionsmedizin und Andrologie, Universitätsklinikum Münster, Münster, Deutschland

    Michael Zitzmann

  2. Zentrum für Reproduktionsmedizin und Andrologie, Universitätsklinikum Halle (Saale), Halle (Saale), Deutschland

    Hermann M. Behre

Authors
  1. Michael Zitzmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hermann M. Behre
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hermann M. Behre .

Editor information

Editors and Affiliations

  1. Centrum für Reproduktionsmedizin und Andrologie, Universitätsklinikum Münster, Münster, Deutschland

    Eberhard Nieschlag

  2. Zentrum für Reproduktionsmedizin und Andrologie, Universitätsklinikum Halle (Saale), Halle (Saale), Deutschland

    Hermann M. Behre

  3. Centrum für Reproduktionsmedizin und Andrologie, Universitätsklinikum Münster, Münster, Deutschland

    Sabine Kliesch

  4. Centrum für Reproduktionsmedizin und Andrologie, Universitätsklinikum Münster, Münster, Deutschland

    Susan Nieschlag

Rights and permissions

Reprints and permissions

Copyright information

© 2023 Springer-Verlag GmbH Deutschland, ein Teil von Springer Nature

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Zitzmann, M., Behre, H.M. (2023). Hypophysär bedingter Hypogonadismus, Hyperprolaktinämie und Gondadotropin-produzierende Tumoren. In: Nieschlag, E., Behre, H.M., Kliesch, S., Nieschlag, S. (eds) Andrologie. Springer Reference Medizin. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-61901-8_15

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-61901-8_15

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-662-61900-1

  • Online ISBN: 978-3-662-61901-8

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation